Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation-Reference-Cited by-同舟云学术

Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation

Published:2006-01-01 Issue:1 Volume:106 Page:136-145
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Schmitz Nobert,Kloess Marita,Reiser Marcel,Berdel Wolfgang E.,Metzner Bernd,Dorken Bernd,Kneba Michael,Trumper Lorenz,Loeffler Markus,Pfreundschuh Michael,Glass Bertram,

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference21 articles.

1. A Predictive Model for Aggressive Non-Hodgkin's Lymphoma

2. Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's Lymphoma

3. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.

4. Survival Benefit of High-Dose Therapy in Poor-Risk Aggressive Non-Hodgkin’s Lymphoma: Final Analysis of the Prospective LNH87–2 Protocol—A Groupe d’Etude des Lymphomes de l’Adulte Study

5. Standard Chemotherapy With or Without High-Dose Chemotherapy for Aggressive Non-Hodgkin's Lymphoma: Randomized Phase III EORTC Study

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of upfront high-dose chemotherapy plus rituximab followed by autologous peripheral blood stem cell transplantation for untreated high-intermediate-, and high-risk diffuse large B-cell lymphoma: a multicenter prospective phase II study (JSCT-NHL04);International Journal of Hematology;2016-03-21

2. Development and Validation of Endovascular Chemotherapy Filter Device for Removing High-Dose Doxorubicin: Preclinical Study;Journal of Medical Devices;2014-08-19

3. The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas;Blood;2014-07-31

4. Myeloid Growth Factors;Infections in Hematology;2014-01-12

5. Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL;SpringerPlus;2014-01-03